作者
Kaspar Broch, Anne Kristine Anstensrud, Sindre Woxholt, Kapil Sharma, Ingvild Maria Tøllefsen, Bjørn Bendz, Svend Aakhus, Thor Ueland, Brage Høyem Amundsen, Jan Kristian Damås, Erlend Sturle Berg, Elisabeth Bjørkelund, Christina Bendz, Einar Hopp, Ola Kleveland, Knut Haakon Stensæth, Anders Opdahl, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Rune Wiseth, Pål Aukrust, Lars Gullestad
发表日期
2021/4/20
期刊
Journal of the American College of Cardiology
卷号
77
期号
15
页码范围
1845-1855
出版商
American College of Cardiology Foundation
简介
Background
Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, as much as 50% of the loss of viable myocardium may be attributed to the reperfusion injury and the associated inflammatory response.
Objectives
This study sought to evaluate the effect of the interleukin-6 receptor inhibitor tocilizumab on myocardial salvage in acute STEMI.
Methods
The ASSAIL-MI trial was a randomized, double-blind, placebo-controlled trial conducted at 3 high-volume PCI centers in Norway. Patients admitted with STEMI within 6 h of symptom onset were eligible. Consenting patients were randomized in a 1:1 fashion to promptly receive a single infusion of 280 mg tocilizumab or placebo. The primary endpoint was the myocardial salvage index as measured by magnetic …
引用总数
学术搜索中的文章